News
ISEE
--
0.00%
--
IVERIC bio, Inc. (ISEE): Hedge Funds Are Snapping Up
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually
Insider Monkey · 09/15 06:02
IVERIC bio to Participate in Upcoming September Investor / Industry Conferences
IVERIC bio announced that the Company will participate in the two upcoming virtual investor conferences and a retina showcase conference in September.
Business Wire · 09/03 12:00
IVERIC Bio Highlights Publication Of GATHER1 Phase 3 Clinical Trial Results For Zimura In Geographic Atrophy Secondary To Age-Related Macular Degeneration, In Ophthalmology, The Journal Of The American Academy Of Ophthalmology
IVERIC bio, Inc. (NASDAQ:ISEE) today announced that the positive Phase 3 results from its GATHER1 clinical trial with Zimura® (avacincaptad pegol), a novel complement C5 inhibitor, in development for the
Benzinga · 09/01 12:46
IVERIC bio Announces Publication of GATHER1 Phase 3 Clinical Trial Results for Zimura® in Geographic Atrophy Secondary to Age-related Macular Degeneration, in Ophthalmology®, the Journal of the American Academy of Ophthalmology
IVERIC announced that the positive Phase 3 results from its GATHER1 clinical trial with Zimura® were published in Ophthalmology®.
Business Wire · 09/01 12:45
IVERIC Bio shares are trading higher after Credit Suisse initiated coverage on the stock with an Outperform rating and a price target of $13 per share.
Benzinga · 08/13 12:31
Credit Suisse Initiates Coverage On IVERIC bio with Outperform Rating, Announces Price Target of $13
Credit Suisse initiates coverage on IVERIC bio (NASDAQ:ISEE) with a Outperform rating and announces Price Target of $13.
Benzinga · 08/13 10:02
IVERIC bio, Inc. 2020 Q2 - Results - Earnings Call Presentation
Seeking Alpha - Article · 08/09 10:30
IVERIC bio, Inc. 2020 Q2 - Results - Earnings Call Presentation
The following slide deck was published by IVERIC bio, Inc. in conjunction with their 2020 Q2 earnings call.
Seekingalpha · 08/09 10:30
IVERIC bio, Inc. 2020 Q2 - Results - Earnings Call Presentation
The following slide deck was published by IVERIC bio, Inc. in conjunction with their 2020 Q2 earnings call.
Seekingalpha · 08/09 10:30
IVERIC bio EPS misses by $0.01
IVERIC bio (NASDAQ:ISEE): Q2 GAAP EPS of -$0.32 misses by $0.01. Cash and equivalents of $245.7M. Shares -0.97% PM. Press Release
seekingalpha · 08/05 16:13
IVERIC bio Reports Second Quarter 2020 Operational Highlights and Financial Results
IVERIC bio today announced the financial and operating results for the fiscal quarter ended June 30, 2020 and provided a general business update.
Business Wire · 08/05 11:00
IVERIC bio to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
IVERIC bio announced Pravin Dugel, MD will present an overview of the Company at the Wedbush PacGrow Healthcare Virtual Conference on Aug. 12, 2020.
Business Wire · 08/04 12:00
IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IVERIC bio reported that the Company granted Dhaval Desai, Chief of Staff, equity based awards pursuant to the 2019 Inducement Stock Incentive Plan.
Business Wire · 08/03 22:55
IVERIC bio to Report Second Quarter 2020 Financial Results and Host Conference Call on Wednesday, August 5, 2020
IVERIC bio today announced that it will report its second quarter 2020 financial and operating results on Wednesday, August 5, 2020.
Business Wire · 07/29 12:00
Did Hedge Funds Make The Right Call On IVERIC bio, Inc. (ISEE) ?
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds
Insider Monkey · 07/17 14:36
IVERIC bio Announces the Addition of Mark S. Blumenkranz, M.D., M.M.S., to its Board of Directors
IVERIC bio announced the election of Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors, effective as of July 15, 2020.
Business Wire · 07/16 12:00
Moving Average Crossover Alert: IVERIC bio
Zacks · 07/03 11:31
Iveric's Trial Progress And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 07/02 07:14
Iveric bio launches second pivotal study of Zimura in eye disorder
Seeking Alpha - Article · 06/30 12:52
IVERIC bio Announces First Patient Dosed in Second Zimura® Phase 3 Clinical Trial for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration
Business Wire · 06/30 12:30